6 analistas têm um consenso de "Compra Moderada" para a Vir Biotecnologia, com um preço-alvo de US $ 33 avg de 12 meses. 6 analysts have a "Moderate Buy" consensus for Vir Biotechnology, with a $33 avg 12-month target price.

A Vir Biotechnology, Inc. (NASDAQ:VIR) tem uma recomendação de consenso de seis analistas que cobrem a empresa, com um preço-alvo médio de 12 meses de US $ 33,00. Vir Biotechnology, Inc. (NASDAQ:VIR) has a "Moderate Buy" consensus recommendation from six analysts covering the firm, with an average 12-month target price of $33.00. A empresa, que se concentra em tratamentos de imunologia para doenças infecciosas graves, viu recentes revisões de preços alvo de corretoras, incluindo Morgan Stanley, Needham & Company LLC, HC Wainwright, JPMorgan Chase & Co. e Barclays. The company, which focuses on immunology treatments for serious infectious diseases, has seen recent price target revisions from brokerages including Morgan Stanley, Needham & Company LLC, HC Wainwright, JPMorgan Chase & Co., and Barclays. Os investidores institucionais possuem 65,32% das ações da Vir Biotechnology. Institutional investors own 65.32% of Vir Biotechnology's stock.